# US 6,730,674 B2 · Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,674 B2
- Document ID: US6730674B2
- Status: Granted
- Kind: B2
- Application number: 10/085,609
- Filed: 2002-02-26
- Published: 2003-01-02
- Granted: 2004-05-04
- Earliest claimed: 2001-02-28
- Assignees: Pfizer Inc.
- Inventors: William H. Martin; Banavara L. Mylari
- Web page: https://patentgrep.com/patent/US6730674B2

## CPC

- C07D 237/18: Sulfur atoms
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to novel sulfonyl pyridazinone compounds of the formula: wherein R1, R2, X, and Y are defined herein, which are useful as aldose reductase inhibitors in the treatment or prevention of certain complications arising from diabetes mellitus, pharmaceutical compositions comprising the sulfonyl pyridazinone, pharmaceutical compositions comprising a combination of the sulfonyl pyridazinone together with a second pharmaceutical agent, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds, therapeutic methods comprising the administration of the sulfonyl pyridazinone compounds in combination with a second pharmaceutical agent and compounds useful as intermediates for preparing the sulfonyl pyridazinone compounds of this invention.

## Claims

### Claim 1

A compound of formula I:
or a pharmaceutically acceptable salt of said compound, wherein,
R1 and R2 are independently hydrogen or methyl,
X is a covalent bond, NR3 or CHR4, wherein,
R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, and R4 is hydrogen or methyl, and
Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, or
X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar,
wherein,
Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, n is independently for each occurrence 0, 1 or 2,
R6 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl, and
R7 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl, with provisos that:
when X is a covalent bond, R1 is hydrogen and R2 is hydrogen, then Y is not an unsubstituted phenyl ring and Y is not a phenyl ring that is mono-substituted at the 4 position with methyl; and
when X is CHR4, R4 is H, R1 is hydrogen and R2 is hydrogen, then Y is not an unsubstituted phenyl ring.

### Claim 2 (depends on 1)

A compound of claim 1 wherein X is a covalent bond.

### Claim 3 (depends on 2)

A compound of claim 2 wherein Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, and O—(C1-C6)alkyl, wherein Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, ON, CF3, (C1C6)alkyl and O—(C1-C6)alkyl.

### Claim 4 (depends on 3)

A compound of claim 3 wherein Y is a first phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, CF3, (C1-C6)alkyl, and O—(1-C6)alkyl, wherein Ar is a second phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, ON, CF3, (C1-C6)alkyl and O—(C1-C6)alkyl, with proviso that said first phenyl or naphthyl ring is substituted with no more than one Ar.

### Claim 5 (depends on 4)

A compound of claim 4 wherein Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F and CF3.

### Claim 6 (depends on 2)

A compound of claim 2 wherein R1 and R2 are both hydrogen.

### Claim 7 (depends on 3)

A compound of claim 3 wherein R1 and R2 are both hydrogen.

### Claim 8 (depends on 4)

A compound of claim 4 wherein R1 and R2 are both hydrogen.

### Claim 9 (depends on 5)

A compound of claim 5 wherein R1 and R2 are both hydrogen.

### Claim 10 (depends on 9)

A compound of claim 9 selected from:
6-(3-trifluoromethyl-benzenesulfonyl)-2H-pyridazin-3-one;
6-(4-bromo-2—fluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(4-trifluoromethyl-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—bromo-benzenesulfonyl)-2H-pyridazin-3-one;
6-(3,4-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(4-methoxy-benzenesulfonyl)-2H-pyridazin-3-one;
6-(3-bromo-benzenesulfonyl)-2H-pyridazin-3-one;
6-(biphenyl-4-sulfonyl)-2H-pyridazin-3-one;
6-(4′-fluoro-biphenyl-4-sulfonyl)-2H-pyridazin-3-one;
6-(4′-trifluoromethyl-biphenyl-4-sulfonyl)-2H-pyridazin-3-one;
6-(3′,5′-bis-trifluoromethyl-biphenyl-4-sulfonyl)-2H-pyridazin-3-one;
6-(biphenyl-2-sulfonyl)-2H-pyridazin-3-one;
6-(4′-trifluoromethyl-biphenyl-2-sulfonyl)-2H-pyridazin-3-one;
6-(2—hydroxy-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—chloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(3-chloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,3-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,5-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(4-fluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(4-chloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—fluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,3-difluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,4-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,4-difluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,6-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—chloro-4-fluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—bromo-4-fluoro-benzenesulfonyl)-2H-pyridazin-3-one; and
6-(naphthalene-1-sulfonyl)-2H-pyridazin-3-one.

### Claim 11 (depends on 10)

A compound of claim 10 selected from:
6-(2—chloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(3-chloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,3-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,5-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(4-fluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(4-chloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—fluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,3-difluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,4-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,4-difluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,6-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—chloro-4-fluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—bromo-4-fluoro-benzenesulfonyl)-2H-pyridazin-3-one; and
6-(naphthalene-1-sulfonyl)-2H-pyridazin-3-one.

### Claim 12 (depends on 11)

A compound of claim 11 selected from:
6-(2—chloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(3-chloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,3-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,5-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,3-difluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,4-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,4-difluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,6-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—chloro-4-fluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—bromo-4-fluoro-benzenesulfonyl)-2H-pyridazin-3-one; and
6-(naphthalene-1-sulfonyl)-2H-pyridazin-3-one.

### Claim 13 (depends on 12)

A compound of claim 12 selected from:
6-(2,3-difluoro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2,4-dichloro-benzenesulfonyl)-2H-pyridazin-3-one;
6-(2—bromo-4-fluoro-benzenesulfonyl)-2H-pyridazin-3-one; and
6-(naphthalene-1-sulfonyl)-2H-pyridazin-3-one.

### Claim 14 (depends on 1)

A compound of claim 1 wherein X is CHR4 wherein R4 is hydrogen or methyl.

### Claim 15 (depends on 14)

A compound of claim 14 wherein Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, and O—(C1-C6)alkyl, wherein Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl and O—(C1-C6)alkyl.

### Claim 16 (depends on 15)

A compound of claim 15 wherein Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, CF3, (C1-C6)alkyl, and O—(C1-C6)alkyl.

### Claim 17 (depends on 14)

A compound of claim 14 wherein R1 and R2 are both hydrogen.

### Claim 18 (depends on 15)

A compound of claim 15 wherein R1 and R2 are both hydrogen.

### Claim 19 (depends on 16)

A compound of claim 16 wherein R1 and R2 are both hydrogen.

### Claim 20 (depends on 19)

A compound of claim 19 selected from:
6-(4-bromo-2-fluoro-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2,6-dichloro-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2—methoxy-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2—fluoro-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(4-chloro-2-fluoro-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2,3,4-trifluoro-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2,4,6-trifluoro-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2—fluoro-3-methyl-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(3-trifluoromethyl-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2,3-dichloro-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2—trifluoromethyl-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2—fluoro-3-trifluoromethyl-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2—chloro-6-fluoro-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(2,3-dichloro-phenylmethanesulfonyl)-2H-pyridazin-3-one;
6-(1-phenyl-ethanesulfonyl)-2H-pyridazin-3-one;
6-[1-(3-trifluoromethyl-phenyl)-ethanesulfonyl]-2H-pyridazin-3-one;
6-[1-(2—trifluoromethyl-phenyl)-ethanesulfonyl]-2H-pyridazin-3-one; and
6-[1-(2,4-dichloro-phenyl)-ethanesulfonyl]-2H-pyridazin-3-one.

### Claim 21 (depends on 1)

A compound of claim 1 wherein X is NR3, wherein R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7.

### Claim 22 (depends on 21)

A compound of claim 21 wherein Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, and O—(C1-C6)alkyl, wherein Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl and O—(C1-C6)alkyl.

### Claim 23 (depends on 21)

A compound of claim 21 wherein R1 and R2 are both hydrogen.

### Claim 24 (depends on 22)

A compound of claim 22 wherein R1 and R2 are both hydrogen.

### Claim 25 (depends on 24)

A compound of claim 24 selected from:
6-oxo-1,6-dihydro-pyridazine-3-sulfonic acid methyl-phenyl-amide;
6-oxo-1,6-dihydro-pyridazine-3-sulfonic acid isopropyl-phenyl-amide; and
6-oxo-1,6-dihydro-pyridazine-3-sulfonic acid (3,4-dichloro-phenyl)-methyl-amide.

### Claim 26 (depends on 1)

A compound of claim 1 wherein R1 and R2 are both hydrogen and X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar.

### Claim 27 (depends on 26)

A compound of claim 26 wherein X and Y together are CH2—CH(OH)—Ar″ or CH2—C(O)—Ar″wherein Ar″ is 4-chlorophenyl.

### Claim 28

A compound of formula XI:
wherein:
R1 and R2 are independently hydrogen or methyl and Z is O—(C1-C6)alkyl, O—Ar, or O—CH2—Ar′, wherein Ar′ is a phenyl ring that is optionally substituted with one or more substituents selected from a halogen, a (C1-C3)alkyl and a O—(C1-C3)alkyl.

### Claim 29 (depends on 28)

A compound of claim 28 wherein R1 and R2 are both hydrogen and Z is methoxy or benzyloxy.

### Claim 30

A pharmaceutical composition comprising a compound of formula I:
wherein,
R1 and R2 are independently hydrogen or methyl,
X is a covalent bond, NR3 or CHR4, wherein,
R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, and R4 is hydrogen or methyl, and
Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, or
X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar,
wherein,
Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7,
n is independently for each occurrence 0, 1 or 2,
R6 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl, and
R7 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl,
or a pharmaceutically acceptable salt of said compound, and a pharmaceutically acceptable vehicle, diluent or carrier.

### Claim 31 (depends on 30)

A pharmaceutical composition of claim 30 wherein said compound of formula I, or a pharmaceutically acceptable salt of said compound, is of an amount effective in inhibiting the enzyme aldose reductase in a mammal affected by diabetes.

### Claim 32 (depends on 31)

A pharmaceutical composition of claim 31 wherein said mammal is a human.

### Claim 33

A pharmaceutical composition comprising a first compound of formula I:
wherein,
R1and R2 are independently hydrogen or methyl,
X is a covalent bond, NR3 or CHR4, wherein,
R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, and R4 is hydrogen or methyl, and
Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, or
X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar,
wherein,
Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, n is independently for each occurrence 0, 1 or 2,
R6 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl, and R7 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl, or a pharmaceutically acceptable salt of said first compound,
and a second compound selected from:
a sorbitol dehydrogenase inhibitor;
a selective serotonin reuptake inhibitor;
a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor;
an angiotensin converting enzyme inhibitor;
a glycogen phosphorylase inhibitor;
an angiotensin II receptor antagonist;
a γ-aminobutyric acid (GABA) agonist;
a phosphodiesterase type 5 inhibitor,
and a pharmaceutically acceptable salt of said second compound.

### Claim 34 (depends on 33)

A pharmaceutical composition of claim 33 wherein said second compound comprises a sorbitol dehydrogenase inhibitor, or a pharmaceutically acceptable salt of said second compound.

### Claim 35 (depends on 33)

A pharmaceutical composition of claim 33 wherein said second compound comprises a selective serotonin reuptake inhibitor, or a pharmaceutically acceptable salt of said second compound.

### Claim 36 (depends on 33)

A pharmaceutical composition of claim 33 wherein said second compound comprises a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, or a pharmaceutically acceptable salt of said second compound.

### Claim 37 (depends on 33)

A pharmaceutical composition of claim 33 wherein said second compound comprises an angiotensin converting enzyme inhibitor, or a pharmaceutically acceptable salt of said second compound.

### Claim 38 (depends on 33)

A pharmaceutical composition of claim 33 wherein said second compound comprises a glycogen phosphorylase inhibitor or a pharmaceutically acceptable salt of said second compound.

### Claim 39 (depends on 33)

A pharmaceutical composition of claim 33 wherein said second compound comprises an angiotensin II receptor antagonist, or a pharmaceutically acceptable salt of said second compound.

### Claim 40 (depends on 33)

A pharmaceutical composition of claim 33 wherein said second compound comprises a γ-aminobutyric acid agonist, or a pharmaceutically acceptable salt of said second compound.

### Claim 41 (depends on 33)

A pharmaceutical composition of claim 33 wherein said second compound comprises a phosphodiesterase type 5 inhibitor, or a pharmaceutically acceptable salt of said second compound.

### Claim 42

A therapeutic method comprising administering to a mammal in need of treatment or prevention of diabetic complications, an aldose reductase inhibiting amount of a compound of formula I:
wherein,
R1 and R2 are independently hydrogen or methyl,
X is a covalent bond, NR3 or CHR4, wherein,
R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, and R4 is hydrogen or methyl, and
Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, or
X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar,
wherein,
Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7,
n is independently for each occurrence 0, 1 or 2,
R6 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl, and
R7 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl,
or a pharmaceutically acceptable salt of said compound.

### Claim 43 (depends on 42)

A therapeutic method of claim 42 wherein said mammal is a human.

### Claim 44

A therapeutic method comprising administering to a mammal in need of treatment or prevention of diabetic complications an aldose reductase inhibiting amount of a first compound of formula I:
wherein,
R1 and R2 are independently hydrogen or methyl,
X is a covalent bond, NR3 or CHR4, wherein,
R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, and R4 is hydrogen or methyl, and
Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, or
X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar,
wherein,
Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7,
n is independently for each occurrence 0, 1 or 2,
R6 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl, and
R7 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl,
and a pharmaceutically acceptable salt of said first compound,
and a second compound selected from:
a sorbitol dehydrogenase inhibitor;
a selective serotonin reuptake inhibitor;
a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor;
an angiotensin converting enzyme inhibitor;
a glycogen phosphorylase inhibitor;
an angiotensin II receptor antagonist;
a γ-aminobutyric acid (GABA) agonist;
a phosphodiesterase type 5 inhibitor,
and a pharmaceutically acceptable salt of said second compound.

### Claim 45 (depends on 44)

A therapeutic method of claim 44 wherein said second compound is a sorbitol dehydrogenase inhibitor and wherein said second compound is administered in a sorbitol dehydrogenase inhibiting amount.

### Claim 46 (depends on 44)

A therapeutic method of claim 44 wherein said second compound is a selective serotonin reuptake inhibitor and wherein said second compound is administered in a selective serotonin reuptake inhibiting amount.

### Claim 47 (depends on 44)

A therapeutic method of claim 44 wherein said second compound is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and wherein said second compound is administered in a hydroxy-3-methylglutaryl coenzyme A reductase inhibiting amount.

### Claim 48 (depends on 44)

A therapeutic method of claim 44 wherein said second compound is an angiotensin converting enzyme inhibitor and wherein said second compound is administered in an angiotensin converting enzyme inhibiting amount.

### Claim 49 (depends on 44)

A therapeutic method of claim 44 wherein said second compound is a glycogen phosphorylase inhibitor and wherein said second compound is administered in a glycogen phosphorylase inhibiting amount.

### Claim 50 (depends on 44)

A therapeutic method of claim 44 wherein said second compound is an angiotensin II receptor antagonist and wherein said second compound is administered in an angiotensin II receptor blocking amount.

### Claim 51 (depends on 44)

A therapeutic method of claim 44 wherein said second compound is a γ-aminobutyric acid agonist and wherein said second compound is administered in a γ-aminobutyric acid receptor binding amount.

### Claim 52 (depends on 44)

A therapeutic method of claim 44 wherein said second compound is a phosphodiesterase type 5 inhibitor and wherein said second compound is administered in a phosphodiesterase type 5 inhibiting amount.

### Claim 53 (depends on 44)

A therapeutic method of claim 44 wherein said mammal is a human.

### Claim 54 (depends on 53)

A process for preparing a compound of formula XII:
comprising reacting a compound of claim 53 with HN(R3)—Y to form a compound of formula XII,
wherein:
Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, wherein Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, n is independently for each occurrence 0, 1 or 2, R6 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl, and R7 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl;
Z is O—(C1-C6)alkyl, O—Ar′, or O—CH2—Ar′, wherein Ar′ is a phenyl ring that is optionally substituted with one or more substituents selected from a halogen and a (C1-C3)alkyl;
R1 and R2 are independently hydrogen or methyl; and
R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—N R6R7.

### Claim 55 (depends on 53)

A process for preparing a compound of formula XIII:
comprising hydrolyzing a compound of formula XII prepared by a method of claim 53 with a mineral acid to form a compound of formula XIII,
wherein:
Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, wherein Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, n is independently for each occurrence 0, 1 or 2, R6 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl, and
R7 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl;
R1 and R2 are independently hydrogen or methyl; and
R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7.

### Claim 56

A kit comprising:
a first dosage form comprising a compound of formula I:
wherein,
R1 and R2 are independently hydrogen or methyl,
X is a covalent bond, NR3 or CHR4, wherein,
R3 is (C1-C3)alkyl or a phenyl that is optionally substituted with one or more substituents selected from OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, and R4 is hydrogen or methyl, and
Y is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from Ar, OH, F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7, or
X and Y together are CH2—CH(OH)—Ar or CH2—C(O)—Ar,
wherein,
Ar is a phenyl or naphthyl ring optionally substituted with one or more substituents selected from F, Cl, Br, I, CN, CF3, (C1-C6)alkyl, O—(C1-C6)alkyl, S(O)n—(C1-C6)alkyl and SO2—NR6R7,
n is independently for each occurrence 0, 1 or 2,
R6 is independently for each occurrence H, (C1-C6)alkyl, phenyl or naphthyl, and
R7 is independently for each occurrence (C1-C6)alkyl, phenyl or naphthyl,
or a pharmaceutically acceptable salt of said compound;
a second dosage form comprising a second compound selected from:
a sorbitol dehydrogenase inhibitor;
a selective serotonin reuptake inhibitor;
a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor;
an angiotensin converting enzyme inhibitor;
a glycogen phosphorylase inhibitor;
an angiotensin II receptor antagonist;
a γ-aminobutyric acid (GABA) agonist;
a phosphodiesterase type 5 inhibitor,
and a pharmaceutically acceptable salt of said compound; and
a container.
